Darolutamide safety study for men with prostate cancer in Korea
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tracks the safety of the drug darolutamide in Korean men with a type of prostate cancer that has not spread (non-metastatic) or has spread (metastatic) and is still responding to hormone therapy. It aims to see how well patients tolerate the drug in real-world settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 19 or older
- You have a type of prostate cancer that is still sensitive to hormone therapy (castration-sensitive)
- Your cancer either has not spread but is at high risk of spreading, or has already spread to other parts of the body
- Your doctor has decided to start you on darolutamide as your first treatment for this condition
- You agree to take part in the study and sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how safe darolutamide is and how well it works when added to standard hormone therapy for men with high-risk, non-metastatic prostate cancer that is no longer responding to hormone treatment. It may help slow prostate cancer growth and reduce prostate-specific antigen (PSA) rises in real-world care.
This study watches how well a drug called darolutamide works when combined with hormone therapy for men with prostate cancer that has returned after previous treatment. The goal is to understand if this combination helps prevent cancer spread and is safe to use.
This trial tests if adding darolutamide to standard hormone therapy works better for men whose prostate cancer has spread but still responds to hormones. It aims to see if this 'triplet therapy' helps men live longer with better control of their cancer.
This study looks at how well darolutamide and similar drugs work for men whose prostate cancer has just spread to other parts of the body. It aims to understand real-world outcomes in urology clinics.
This trial tests the drug darolutamide for men whose prostate cancer has spread and is no longer controlled by standard hormone therapy. It may be an option if you've already had certain hormone treatments for at least 12 months but your cancer is still progressing.
This trial tests a new way of using darolutamide (a hormone therapy) together with standard chemotherapy (docetaxel) and hormone therapy (ADT) for men with prostate cancer that has spread. The goal is to see if taking darolutamide on an intermittent schedule works as well as continuous treatment.
Hear when a new Non-metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.